Innovation

20 posts

Case Study: VEXAS Syndrome

vexas disease- Bone Marrow Aspirate NEJM

Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of the protein and resulting in decreased cellular ubiquitylation activity and hyperinflammation. This is an adults-onset fatal disease that may present as myelodysplastic syndrome, aplastic anemia or multiple myeloma, but characterized […]

Read More

Genomic Testing Cooperative to Reveal “Liquid Trace™” at ASCO, a Liquid Biopsy Test that Combines Cell-Free DNA with Targeted Transcriptome and to Present Data on its Advanced AI for the Diagnosis of Hematologic and Solid Tumors

Irvine, California– June 1, 2022 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO) 2022 annual meeting data showcasing its new innovative approach to liquid biopsy testing that combines both cell-free-DNA (cfDNA) with cell-free RNA (cfRNA), Liquid Trace™. Liquid Trace tests both cfDNA and […]

Read More

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Abstract Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap clinically. Using machine learning, we developed an approach to stratify patients with DLBCL into four subgroups based on survival characteristics. This approach uses data from the targeted transcriptome to predict […]

Read More

GTC at ASH 2021

GTC is excited to be exhibiting at ASH for the first time and look forward to meeting people in person.  Our booth # 3440 and would like you will stop by and say hello.   If you would like to schedule a meeting fill out the form below  We have four abstracts being presented at ASH – here is […]

Read More

Do not Accept partial results about PH-Like Acute Lymphoblastic Leukemia

DNA RNA ALL

Distinguishing PH-like acute lymphoblastic leukemia (ALL) from other types of ALL relies on full evaluation of the molecular abnormalities in the leukemic cells. Order GTC Hematology Molecular Profile Plus GTC Hematology Profile Plus and obtain complete evaluation of mutations in DNA of 177 genes and fusion/expression/mutations in RNA of 1408 genes. Here is an example […]

Read More

Time Matters on Health Tests [TAT-NGS]

Turn Around Time, Turnaround Time, TAT, NGS (Next Generation Sequencing), Next-Gen, NGS, TTI (Time to Treatment Initiation), GTC

We’re always competing with ourselves on improving turn around time (TAT) because we know patients depend on the results Most studies suggest that treatment delay leads to a worse outcome Patients with cancer who have to wait longer for treatment suffer from significant anxiety and stress Physicians and patients deserve to get the results of […]

Read More

Looking for an answer quickly from your NGS provider?

fast reliable NGS testing for cancer

Time Matters on Health Tests When dealing with cancer, clinicians and patients need to know the results of molecular testing as soon as possible.  Are you waiting 21-28 days to receive your NGS results? Genomic Testing Cooperative (GTC) is using disruptive technology and will report results within 7 days of receiving the sample.  GTC tests […]

Read More

CSI Laboratories is the first to offer 177 gene liquid biopsy for hematology

CSI Laboratories is a specialized cancer diagnostics center

-a step forward to precision in cancer diagnostics- CSI LABORATORIES ADVANCES BY PARTNERING WITH DR. MAHER ALBITAR OF GENOMICS TESTING COOPERATIVE (GTC)  Membership in the Co-Op also makes CSI Laboratories the first to offer 177 gene liquid biopsy for hematology   ALPHARETTA –   CSI Laboratories, nationally renowned for its quality cancer diagnostics, goes a step forward to precision […]

Read More

Acute Lymphoblastic Leukemia | Just published: A consensus of North American experts

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts The vast majority of adults with acute lymphoblastic leukemia (ALL) achieve remission with standard chemotherapy regimens, but many of these patients ultimately relapse and die from leukemia. In these patients, relapse occurs despite achievement of morphologic remission (ie, […]

Read More